Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNJ013
MIFTS: 63

Conjunctivitis

Categories: Eye diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Conjunctivitis

About this section

MalaCards integrated aliases for Conjunctivitis:

Name: Conjunctivitis 12 76 29 55 3 44 15 63 73
Madras Eye 12

Classifications:

MalaCards categories:
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:6195
ICD10 33 H10 H10.9
ICD9CM 35 372.30
MeSH 44 D003231
NCIt 50 C34504
UMLS 73 C0009763
Sources

Summaries for Conjunctivitis

About this section
PubMed Health : 63 About conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other.Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks.Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary : Conjunctivitis, also known as madras eye, is related to giant papillary conjunctivitis and papillary conjunctivitis, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Oralair and Zinc have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

CDC : 3 People often call conjunctivitis “pink eye” because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Wikipedia : 76 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Sources

Related Diseases for Conjunctivitis

About this section

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 626)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 33.9 CCL11 CXCL8 IL4 RNASE3
2 papillary conjunctivitis 33.4 CCL11 CXCL8 IL4 IL6
3 blepharoconjunctivitis 33.2 CCL11 IL4 RNASE3
4 chronic conjunctivitis 33.1 CCL11 IL13 IL4 IL5 RNASE3
5 measles 31.9 IFNG IL2 IL4 IL6
6 vernal conjunctivitis 31.1 EPX IFNG IL2 IL4 MS4A2 RNASE3
7 chlamydia 30.8 CXCL8 IFNG IL6
8 gingivitis 30.4 CXCL8 IL4 IL6
9 prostatitis 30.4 CXCL8 IL2 IL6
10 allergic conjunctivitis 30.1 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
11 uveitis 30.1 ICAM1 IFNG IL4
12 hematopoietic stem cell transplantation 30.0 IFNG IL2 IL6
13 sinusitis 29.9 CXCL8 IL5 RNASE3
14 coccidiosis 29.9 IFNG IL2 IL4
15 aggressive periodontitis 29.8 CXCL8 IL4 IL6
16 necrotizing fasciitis 29.8 CXCL8 IL2 IL6
17 myasthenia gravis 29.7 IFNG IL2 IL4
18 bullous pemphigoid 29.7 CCL11 IL5 RNASE3
19 viral infectious disease 29.7 CXCL8 IFNG IL2 IL4 IL6
20 otitis media 29.7 CCL11 CXCL8 IL6 RNASE3
21 spondyloarthropathy 29.6 IFNG IL2 IL4 IL6
22 poliomyelitis 29.6 ICAM1 IFNG IL4
23 urticaria 29.6 MS4A2 NLRP3 RNASE3
24 osteomyelitis 29.6 CXCL8 IFNG IL6
25 pneumonia 29.5 CCL11 CXCL8 IL13 IL5 IL6
26 periodontitis 29.5 CXCL8 IFNG IL4 IL6
27 lichen planus 29.5 ICAM1 IFNG IL4
28 scleritis 29.4 IL4 IL5
29 pollen allergy 29.4 EPX ICAM1 IL13 IL5 RNASE3
30 mastitis 29.4 CXCL8 ICAM1 IL6
31 wegener granulomatosis 29.4 CXCL8 IFNG IL6
32 synovitis 29.4 CXCL8 ICAM1 IL6
33 meningitis 29.3 CXCL8 IFNG IL6 NLRP3
34 common variable immunodeficiency 29.3 IFNG IL2 IL4 IL6
35 interstitial lung disease 29.2 CXCL8 IFNG IL4 IL6
36 dermatitis 29.1 CCL11 IFNG IL13 IL4 IL5 RNASE3
37 vernal keratoconjunctivitis 28.9 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
38 autoimmune disease 28.6 IFNG IL2 IL4 IL5 IL6
39 peritonitis 28.6 CXCL8 ICAM1 IL6 MUC16
40 systemic lupus erythematosus 28.5 ICAM1 IFNG IL2 IL4 IL6
41 rheumatoid arthritis 28.3 CXCL8 ICAM1 IFNG IL2 IL4 IL6
42 keratoconjunctivitis 28.1 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
43 ige responsiveness, atopic 28.1 IFNG IL13 IL4 IL5 MS4A2 RNASE3
44 contact dermatitis 28.0 CXCL8 ICAM1 IFNG IL4 IL5 IL6
45 atopic keratoconjunctivitis 27.9 IFNG IL2 IL4 IL5 MUC16 RNASE3
46 rhinitis 27.1 CCL11 CXCL8 EPX ICAM1 IL13 IL4
47 allergic rhinitis 26.9 CCL11 CXCL8 EPX ICAM1 IFNG IL13
48 upper respiratory tract disease 26.7 CCL11 CXCL8 IL13 IL33 IL4 IL5
49 malaria 26.2 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
50 inflammatory bowel disease 24.8 CCL11 CXCL8 EPX ICAM1 IFNG IL13

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 21)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Blepharitis
Bronchitis Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Ischemic Heart Disease
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis
Sources

Symptoms & Phenotypes for Conjunctivitis

About this section

UMLS symptoms related to Conjunctivitis:


bloodshot eye, conjunctival congestion, redness of eye, discharge from eye

MGI Mouse Phenotypes related to Conjunctivitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 IL13 IL5 IL2 CCL11 EPX ICAM1
2 immune system MP:0005387 10.18 IL13 IL5 IL2 CCL11 EPX ICAM1
3 digestive/alimentary MP:0005381 10.16 IL13 IL5 IL2 ICAM1 IL33 IFNG
4 endocrine/exocrine gland MP:0005379 10.03 IL4 IL13 IL2 ICAM1 IL33 IFNG
5 integument MP:0010771 9.92 IL13 ICAM1 IL33 IFNG IL4 PLG
6 liver/biliary system MP:0005370 9.8 IL4 IL5 IL2 IFNG PLG IL6
7 neoplasm MP:0002006 9.63 IL2 ICAM1 IFNG PLG IL5 IL6
8 reproductive system MP:0005389 9.61 IL13 IL5 IL2 IL33 IFNG IL4
9 respiratory system MP:0005388 9.28 IL13 IL5 IL2 CCL11 IL33 IFNG
Sources

Drugs & Therapeutics for Conjunctivitis

About this section

PubMedHealth treatment related to Conjunctivitis: 63

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection, even though conjunctivitis is more commonly caused by viruses. But antibiotics are only effective against bacteria, and have no effect on viruses. If the infection is viral, only the symptoms can be treated.Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful.If conjunctivitis is caused by an allergy, it can be treated with allergy medicine such as antihistamines.

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Oralair 18 Greer Labs April 2014

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 23994
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 9004-61-9 53477741
3
Glycerol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-81-5 753
4
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 82410-32-0 3454
5
Loteprednol Approved Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
6
Ephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 299-42-3 9294
7
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 90-82-4 7028
8
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
10
Iodine Approved, Investigational Phase 4,Phase 3,Not Applicable 7553-56-2 807
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
12
Tobramycin Approved, Investigational Phase 4,Phase 3,Not Applicable 32986-56-4 5496 36294
13
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492
14
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
15
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
16
Naphazoline Approved Phase 4,Phase 3 835-31-4 4436
17
Pheniramine Approved Phase 4 86-21-5 4761
18
Dipivefrin Approved Phase 4,Phase 3,Phase 2 52365-63-6 3105
19
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 90566-53-3 62924
20
Povidone Approved Phase 4,Phase 3,Not Applicable 9003-39-8
21
Ivermectin Approved, Investigational, Vet_approved Phase 4,Not Applicable 70288-86-7 6474909
22
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
23
Menthol Approved Phase 4,Phase 3,Not Applicable 2216-51-5 16666
24
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
25
Albendazole Approved, Vet_approved Phase 4,Not Applicable 54965-21-8 2082
26
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
27
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 55185 447043
28
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
29
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
30
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
31
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
32
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-14-8, 34580-13-7 3827
33
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
34 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 979-32-8
35
Montelukast Approved Phase 4 158966-92-8 5281040
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
37
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
38
Tranilast Approved, Investigational Phase 4 53902-12-8 93543
39
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2 35189-28-7 6540478
40
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
41
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
42
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
43
Epinephrine Approved, Vet_approved Phase 4,Phase 3 51-43-4 5816
44
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
45
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
46
Pimecrolimus Approved, Investigational Phase 4,Not Applicable 137071-32-0 6447131 17753757
47
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
48
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
49
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
50
Racepinephrine Approved Phase 4,Phase 3 329-65-7 838

Interventional clinical trials:

(show top 50) (show all 883)
# Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
4 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
5 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
6 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
7 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
8 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
9 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
10 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
11 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
12 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
13 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
14 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
15 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
16 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
17 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
18 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
19 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
20 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
21 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
22 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
23 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
24 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
25 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
26 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
27 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
28 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
29 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
30 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
31 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
32 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
33 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
34 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
35 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
36 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Artificial tears
37 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
38 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
39 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
40 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
41 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
42 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) Completed NCT02256553 Phase 4 Rescue Medication
43 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
44 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
45 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
46 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
47 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
48 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
49 The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
50 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: conjunctivitis

Sources

Genetic Tests for Conjunctivitis

About this section

Genetic tests related to Conjunctivitis:

# Genetic test Affiliating Genes
1 Conjunctivitis 29
Sources

Anatomical Context for Conjunctivitis

About this section

MalaCards organs/tissues related to Conjunctivitis:

41
Eye, Testes, Skin, T Cells, Thyroid, Bone, Lung
Sources

Publications for Conjunctivitis

About this section

Articles related to Conjunctivitis:

(show top 50) (show all 1987)
# Title Authors Year
1
Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels? Reply from authors. ( 29336016 )
2018
2
Conjunctivitis, mucosal erosions, and moist cutaneous plaques. ( 29349113 )
2018
3
Coronally advanced flap in conjunction with platelet-rich fibrin-assisted immediate management of residual gingival defect following surgical excision of recurrent pyogenic granuloma in the maxillary esthetic segment. ( 29962710 )
2018
4
Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand. ( 29921954 )
2018
5
Seasonal and Temporal Trends in Childhood Conjunctivitis in Burkina Faso. ( 29761759 )
2018
6
Pseudoallergic conjunctivitis induced by tamsulosin, a selective alpha-1 adrenergic receptor antagonist. ( 29705339 )
2018
7
Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis. ( 29787732 )
2018
8
Coxsackievirus A24 Variant Associated with Acute Haemorrhagic Conjunctivitis Cases, French Guiana, 2017. ( 29898445 )
2018
9
The role of previous falls in major osteoporotic fracture prediction in conjunction with FRAX in older Chinese men and women: the Mr. OS and Ms. OS cohort study in Hong Kong. ( 29651509 )
2018
10
Bacterial conjunctivitis in childhood: etiology, clinical manifestations, diagnosis, and management. ( 29380707 )
2018
11
Dacryoadenitis due to gonococcal conjunctivitis complicated by corneal perforation. ( 29565715 )
2018
12
Treatment with galectin-1 eye drops regulates mast cell degranulation and attenuates the severity of conjunctivitis. ( 29859836 )
2018
13
Contact lenses with dual drug delivery for the treatment of bacterial conjunctivitis. ( 29960036 )
2018
14
Variation in the TEK gene is not associated with asthma but with allergic conjunctivitis. ( 29667338 )
2018
15
Ocular Munchhausen's syndrome: Self-inflicted conjunctivitis. ( 29903587 )
2018
16
Editorial Commentary: Distal Mononeuropathy in Conjunction With Rotator Cuff Repair: Don't Forget the Preoperative Assessment. ( 29622255 )
2018
17
A novel herpesvirus associated with chronic superficial keratitis and proliferative conjunctivitis in a great horned owl (Bubo virginianus). ( 29656541 )
2018
18
Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis. ( 29615844 )
2018
19
Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. ( 29543548 )
2018
20
Conjunctivitis Occurring in Atopic Dermatitis Patients Treated with Dupilumab - Clinical Characteristics and Treatment. ( 29432961 )
2018
21
Allergic conjunctivitis: current concepts on pathogenesis and management. ( 29552874 )
2018
22
Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression. ( 29398596 )
2018
23
A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. ( 29392313 )
2018
24
The role of previous falls in major osteoporotic fracture prediction in conjunction with FRAX in older Chinese men and women: the Mr. OS and Ms. OS cohort study in Hong Kong. ( 29067485 )
2018
25
Tear osteopontin level and its relationship with local Th1/Th2/Th17/Treg cytokines in children with allergic conjunctivitis. ( 29279263 )
2018
26
Utilization of manual therapy to the lumbar spine in conjunction with traditional conservative care for individuals with bilateral lower extremity complex regional pain syndrome: A case series. ( 29873592 )
2018
27
Aetiology of neonatal conjunctivitis evaluated in a population-based setting. ( 29345007 )
2018
28
Rapamycin attenuates Th2-driven experimental allergic conjunctivitis. ( 29432811 )
2018
29
Sublingual immunotherapy for pediatric allergic conjunctivitis: a meta-analysis of randomized controlled trials. ( 29782067 )
2018
30
Re: Keen etA al.: Treatment of acute conjunctivitis in the United States and evidence of antibiotic overuse: isolated issue or a systematic problem? (Ophthalmology. 2017;124:1096-1098). ( 29935672 )
2018
31
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). ( 29416652 )
2018
32
Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis. ( 29847658 )
2018
33
Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis. ( 29719638 )
2018
34
Spatial analysis between particulate matter and emergency room visits for conjunctivitis and keratitis. ( 29942521 )
2018
35
Chronic Follicular Conjunctivitis in a Middle-aged Woman. ( 29801089 )
2018
36
Five-year trends in adenoviral conjunctivitis in employees of one medical center. ( 29950191 )
2018
37
Adenovirus-associated acute conjunctivitis in Beijing, China, 2011-2013. ( 29558885 )
2018
38
Clinical Age-Specific Seasonal Conjunctivitis Patterns and Their Online Detection in Twitter, Blog, Forum, and Comment Social Media Posts. ( 29450538 )
2018
39
Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with demodex and increased IL-17 levels? ( 29333603 )
2018
40
Effect of PycnogenolAr on an experimental rat model of allergic conjunctivitis. ( 29675725 )
2018
41
Molecular epidemiology of circulating human adenovirus types in acute conjunctivitis cases in Chandigarh, North India. ( 29735838 )
2018
42
Fuchs syndrome: a case of fever, mucositis and conjunctivitis. ( 29378740 )
2018
43
Treatment of gingival recession by coronally advanced flap in conjunction with platelet-rich fibrin or resin-modified glass-ionomer restoration: A clinical study. ( 29568172 )
2018
44
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. ( 29624493 )
2018
45
Amniotic membrane transplantation for ligneous conjunctivitis in a doberman. ( 29482261 )
2018
46
Novel hydrogel-based ocular drug delivery system for the treatment of conjunctivitis. ( 29922978 )
2018
47
Therapeutic and Analgesic Efficacy of Laser in Conjunction With Pharmaceutical Therapy for Trigeminal Neuralgia. ( 29399314 )
2018
48
Role of enhanced receptor engagement in the evolution of a pandemic acute hemorrhagic conjunctivitis virus. ( 29284752 )
2018
49
Unusual Presentations of Coccidioidomycosis in Conjunction With Autoimmune Syndromes: A Literature Review and Case Series. ( 29912770 )
2018
50
Costs of Conjunctivitis Outbreak, RAcunion Island, France. ( 29260662 )
2018
Sources

Variations for Conjunctivitis

About this section
Sources

Expression for Conjunctivitis

About this section
Search GEO for disease gene expression data for Conjunctivitis.
Sources

Pathways for Conjunctivitis

About this section

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.96 CCL11 CXCL8 EPX ICAM1 IFNG IL13
2
PEDF Induced Signaling 64
Show member pathways
 13.65 CCL11 CXCL8 IFNG IL13 IL2 IL33
3
TGF-Beta Pathway 64
Show member pathways
 13.49 CCL11 CXCL8 IFNG IL13 IL2 IL4
4
Cytokine Signaling in Immune system 66
Show member pathways
 13.38 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
5
Akt Signaling 64
Show member pathways
 13.37 CCL11 CXCL8 IL13 IL2 IL4 IL5
6
PAK Pathway 64
Show member pathways
 13.27 CCL11 CXCL8 IL13 IL2 IL4 IL5
7
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 12.97 CXCL8 IFNG IL2 IL6 NLRP3
8
Pathways in cancer 37
12.88 CXCL8 IFNG IL13 IL2 IL4 IL5
9
Influenza A 37
Show member pathways
 12.76 CXCL8 ICAM1 IFNG IL13 IL2 IL33
10
Regulation of IFNA signaling 66
Show member pathways
 12.7 CXCL8 IFNG IL13 IL2 IL4 IL5
11
Immune response IL-23 signaling pathway 22
Show member pathways
 12.55 IFNG IL2 IL6 PLG
12
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.54 IL13 IL4 IL5 MS4A2
13
Th17 cell differentiation 37
Show member pathways
 12.51 IFNG IL13 IL2 IL4 IL5 IL6
14
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.48 ICAM1 IFNG IL2 IL4
15
Allograft rejection 1 37
Show member pathways
 12.47 CCL11 CXCL8 EPX ICAM1 IFNG IL13
16
T cell receptor signaling pathway 37
Show member pathways
 12.44 IFNG IL2 IL4 IL5 IL6
17
Folate Metabolism 1
Show member pathways
 12.4 ICAM1 IFNG IL2 IL4 IL6 PLG
18
IL-17 Family Signaling Pathways 65
Show member pathways
 12.39 CCL11 CXCL8 IFNG IL13 IL4 IL5
19
Bacterial infections in CF airways 22
Show member pathways
 12.24 CCL11 CXCL8 IFNG IL4 IL6
20
Spinal Cord Injury 1
12.09 CXCL8 ICAM1 IFNG IL2 IL4 IL6
21
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.07 IFNG IL2 IL4 IL5 IL6
22
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.07 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
23
Interleukin-4 and 13 signaling 66
12.06 CCL11 CXCL8 ICAM1 IL13 IL4 IL6
24
MAPK Pathway 72
Show member pathways
 11.99 IL13 IL2 IL5
25
IL12-mediated signaling events 1
Show member pathways
 11.94 IFNG IL2 IL4
26
Senescence and Autophagy in Cancer 1
11.91 CXCL8 IFNG IL6
27
Rheumatoid arthritis 37
11.89 CXCL8 ICAM1 IFNG IL6
28
AGE-RAGE signaling pathway in diabetic complications 37
11.88 CXCL8 ICAM1 IL6
29
Hematopoietic cell lineage 37
11.86 IL4 IL5 IL6
30
Amoebiasis 37
11.86 CXCL8 IFNG IL6
31
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.86 CXCL8 IFNG IL2 IL4 IL5
32
Innate Lymphoid Cell Differentiation Pathways 65
11.86 IFNG IL13 IL2 IL33 IL4 IL5
33
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.84 CXCL8 ICAM1 IL6
34
Salmonella infection (KEGG) 37
11.8 CXCL8 IFNG IL6
35
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.76 CXCL8 ICAM1 IFNG IL2 IL6
36
Pertussis 37
11.75 CXCL8 IL6 NLRP3
37
Dendritic Cells Developmental Lineage Pathway 65
11.73 IFNG IL2 IL6
38
Lung fibrosis 1
11.71 CCL11 CXCL8 IL13 IL4 IL5 IL6
39
IL4-mediated signaling events 1
11.66 CCL11 IL4 IL5
40
Interleukin-10 signaling 66
11.64 CXCL8 ICAM1 IL13 IL4 IL6
41
Malaria 37
11.61 CXCL8 ICAM1 IFNG IL6
42
ATF-2 transcription factor network 1
11.6 CXCL8 IFNG IL6
43
Photodynamic therapy-induced AP-1 survival signaling. 1
11.56 IFNG IL2 IL6
44
amb2 Integrin signaling 1
11.53 ICAM1 IL6 PLG
45
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.52 CCL11 CXCL8 IL6
46
Immune response_Role of integrins in NK cells cytotoxicity 22
11.48 CXCL8 ICAM1 IFNG
47
Inflammatory Response Pathway 1
11.42 IFNG IL2 IL4 IL5
48
African trypanosomiasis 37
11.37 ICAM1 IFNG IL6
49
Th2 Differentiation Pathway 65
11.36 CCL11 IFNG IL13 IL2 IL33 IL4
50
Development and heterogeneity of the ILC family 1
11.3 IFNG IL13 IL33 IL4 IL5 IL6
Sources

GO Terms for Conjunctivitis

About this section

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 CCL11 CXCL8 EPX IFNG IL13 IL2
2 extracellular space GO:0005615 9.47 CCL11 CXCL8 EPX ICAM1 IFNG IL13

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.87 CCL11 CXCL8 IL13 IL5 IL6 MS4A2
2 defense response to virus GO:0051607 9.83 IFNG IL33 IL6 NLRP3
3 cellular response to tumor necrosis factor GO:0071356 9.81 CCL11 CXCL8 ICAM1
4 response to ethanol GO:0045471 9.8 ICAM1 IL13 IL2
5 cellular response to lipopolysaccharide GO:0071222 9.8 CXCL8 ICAM1 IL6 NLRP3
6 defense response to Gram-positive bacterium GO:0050830 9.78 IL6 NLRP3 RNASE3
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.77 ICAM1 IL5 IL6
8 cellular response to interleukin-1 GO:0071347 9.77 CCL11 CXCL8 ICAM1
9 cytokine-mediated signaling pathway GO:0019221 9.76 CCL11 CXCL8 ICAM1 IL13 IL2 IL4
10 positive regulation of T cell proliferation GO:0042102 9.74 IL2 IL4 IL6
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IFNG IL13 IL2 IL6
12 positive regulation of B cell proliferation GO:0030890 9.67 IL13 IL2 IL4 IL5
13 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 ICAM1 IL13 IL4
14 positive regulation of T cell differentiation GO:0045582 9.63 IL2 IL4
15 positive regulation of interleukin-4 production GO:0032753 9.63 EPX IL33 NLRP3
16 regulation of regulatory T cell differentiation GO:0045589 9.62 IFNG IL2
17 positive regulation of macrophage activation GO:0043032 9.61 IL13 IL33
18 immune response GO:0006955 9.61 CCL11 CXCL8 IFNG IL13 IL2 IL4
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 IL2 IL4
20 positive regulation of interleukin-5 production GO:0032754 9.58 IL33 NLRP3
21 positive regulation of interleukin-13 production GO:0032736 9.58 IL33 IL4 NLRP3
22 type 2 immune response GO:0042092 9.56 IL33 IL4
23 positive regulation of immunoglobulin secretion GO:0051024 9.56 IL2 IL33 IL5 IL6
24 positive regulation of type 2 immune response GO:0002830 9.55 IL33 NLRP3
25 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.54 IL6 NLRP3
26 negative regulation of complement-dependent cytotoxicity GO:1903660 9.51 IL13 IL4
27 regulation of signaling receptor activity GO:0010469 9.28 CCL11 CXCL8 IFNG IL13